Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
TOKYO and CAMBRIDGE, Mass., Jan 27, 2023 – (JCN Newswire via SEAPRWire.com) – …
Read Moreทุกอย่างในกรุงเทพ: เรื่องจริงและผู้คนในเมืองกรุงเทพ | Stories & People in Bangkok city
TOKYO and CAMBRIDGE, Mass., Jan 27, 2023 – (JCN Newswire via SEAPRWire.com) – …
Read MoreTOKYO and CAMBRIDGE, Mass., Jan 16, 2023 – (JCN Newswire via SEAPRWire.com) – …
Read MoreTOKYO, Jan 11, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and B…
Read MoreNEW YORK, NY,October 06, 2022- (SEAPRWire) – Audiolox, a blockchain-powered and secure mus…
Read MoreContinuously expanding the scope of potential indications for SN1011 HONG KONG, June 9, 20…
Read MoreTOKYO, May 10, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. today…
Read MoreHONG KONG, Apr 20, 2022 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScienc…
Read MoreKuala Lumpur, Malaysia / SEAPRWire / July 30, 2021 / – Mobile devices like…
Read MoreSINGAPORE, Mar 12, 2021 – (ACN Newswire via SEAPRWire.com) – A first-of-its-ki…
Read MoreSINGAPORE, Mar 11, 2021 – (ACN Newswire via SEAPRWire.com) – A first-of-its-ki…
Read More